Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use

With the introduction of the complement C5-inhibitor eculizumab, a new era was entered for patients with atypical hemolytic uremic syndrome (aHUS). Eculizumab therapy very effectively reversed thrombotic microangiopathy and reduced mortality and morbidity. Initial guidelines suggested lifelong treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wijnsma, Kioa L., Duineveld, Caroline, Wetzels, Jack F. M., van de Kar, Nicole C. A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794245/
https://www.ncbi.nlm.nih.gov/pubmed/30402748
http://dx.doi.org/10.1007/s00467-018-4091-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794245/
https://www.ncbi.nlm.nih.gov/pubmed/30402748
http://dx.doi.org/10.1007/s00467-018-4091-3

Ejemplares similares